Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONESHOT: Single-Dose Neoadjuvant Nivolumab in Resectable Hepatocellular Carcinoma
NCT07902258Phase 2Not yet recruiting
- Sponsor
- National Taiwan University Hospital
- Start
- Nov 2026
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in hepatocellular carcinoma (HCC), sponsored by National Taiwan University Hospital. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07902258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07902258.